DeepCure Raises $24M to Propel AI-Driven Drug Discovery Forward
DeepCure, a spin-out from MIT, aims to revolutionize small molecule therapeutics discovery using artificial intelligence (AI) and automated chemistry, addressing challenging targets in the pharmaceutical industry.
Company Name: DeepCure
Location: Boston, MA
Sector: Biotechnology
Funding Details: Raised $24M in Series A-1 funding led by IAG Capital Partners (IAG), with participation from current investors.
Purpose of Investment: To further develop its technology and advance its immunology and inflammation pipeline towards clinical trials.
Leadership: Led by CEO Kfir Schreiber
Product: A generative AI and physics-based engine for small molecule therapy discovery and an advanced automated chemistry synthesis platform for rapidly testing a diverse range of molecules.
About Company: DeepCure, a spin-out from MIT, aims to revolutionize small molecule therapeutics discovery using artificial intelligence (AI) and automated chemistry, addressing challenging targets in the pharmaceutical industry.
